蛋白激酶抑制剂在类风湿性关节炎的研究进展

Research Progress of Protein Kinase Inhibitors in Rheumatoid Arthritis

类风湿性关节炎(Rheumatoid arthritis,RA)的发病率高、患病人口多,目前抗风湿性关节炎疾病缓解药物(disease-modifying antirheumatic drug,DMARD)主要是针对关键细胞因子靶点的生物制剂,但生物制剂面临着患者需要反复注射、价格昂贵等不足而不能满足RA的治疗。新开发DMARD药物已有针对Janus激酶(Januskinase,JAK)、脾酪氨酸激酶(spleen tyrosine kinase,Syk)、p38激酶的抑制剂进入临床试验研究,蛋白激酶抑制剂的研发将为RA的治疗带来新的方法。

Rheumatoid arthritis（RA） is a high incidence of autoimmune diseases with a large prevalence of population. Biological agents currently dominate the market for disease-modifying for RA, which target the key cytokines. Biological agents are also faced with many shortcomings,such as the requirement of repeated injections, expensive, and sometimes are ineffective in the treatment of RA. Nowadays, new generations of DMARDs, the inhibitors of Janus kinase, spleen tyrosine kinase and p38 kinase, have been entered the clinical trials. The development of those protein kinase inhibitors will open a new approach for the treatment of RA.